KR101799008B1 - Pharmaceutical composition for treating fungal infections of keratinous tissue - Google Patents
Pharmaceutical composition for treating fungal infections of keratinous tissue Download PDFInfo
- Publication number
- KR101799008B1 KR101799008B1 KR1020160028730A KR20160028730A KR101799008B1 KR 101799008 B1 KR101799008 B1 KR 101799008B1 KR 1020160028730 A KR1020160028730 A KR 1020160028730A KR 20160028730 A KR20160028730 A KR 20160028730A KR 101799008 B1 KR101799008 B1 KR 101799008B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- pharmaceutical composition
- delete delete
- present
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 206010017533 Fungal infection Diseases 0.000 title abstract description 6
- 208000031888 Mycoses Diseases 0.000 title abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 29
- 239000003960 organic solvent Substances 0.000 claims abstract description 24
- 230000003113 alkalizing effect Effects 0.000 claims abstract description 19
- 238000010521 absorption reaction Methods 0.000 claims abstract description 8
- 102000011782 Keratins Human genes 0.000 claims abstract description 7
- 108010076876 Keratins Proteins 0.000 claims abstract description 7
- 208000024386 fungal infectious disease Diseases 0.000 claims abstract description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 7
- 229940008099 dimethicone Drugs 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 3
- 229940086555 cyclomethicone Drugs 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 claims 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 47
- 229940121375 antifungal agent Drugs 0.000 abstract description 41
- 239000013543 active substance Substances 0.000 abstract description 34
- 230000000843 anti-fungal effect Effects 0.000 abstract description 31
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract 1
- 210000000282 nail Anatomy 0.000 description 28
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 18
- 230000035699 permeability Effects 0.000 description 15
- 208000010195 Onychomycosis Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- -1 cyclopirox Chemical class 0.000 description 12
- 210000004906 toe nail Anatomy 0.000 description 12
- 239000003429 antifungal agent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 210000004247 hand Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241001480043 Arthrodermataceae Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 239000011149 active material Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000037304 dermatophytes Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010033892 Paraplegia Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 229960002722 terbinafine Drugs 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 2
- CDLZUDXUPFCTRJ-UHFFFAOYSA-N 1,1-di(propan-2-yl)hydrazine Chemical compound CC(C)N(N)C(C)C CDLZUDXUPFCTRJ-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 244000100945 Piper peltatum Species 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000000003 hoof Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- MBNMGGKBGCIEGF-UHFFFAOYSA-N 1,1-diethoxypropane Chemical compound CCOC(CC)OCC MBNMGGKBGCIEGF-UHFFFAOYSA-N 0.000 description 1
- IFZHGQSUNAKKSN-UHFFFAOYSA-N 1,1-diethylhydrazine Chemical compound CCN(N)CC IFZHGQSUNAKKSN-UHFFFAOYSA-N 0.000 description 1
- ZCBQRUIWOOEFCB-UHFFFAOYSA-N 1,3-diethylpyrrolidin-2-one Chemical compound CCC1CCN(CC)C1=O ZCBQRUIWOOEFCB-UHFFFAOYSA-N 0.000 description 1
- VATWWPXJGLAOSW-UHFFFAOYSA-N 1-(2-chloroethyl)-2-methylhydrazine Chemical compound CNNCCCl VATWWPXJGLAOSW-UHFFFAOYSA-N 0.000 description 1
- MXDYUONTWJFUOK-UHFFFAOYSA-N 1-(azepan-1-yl)dodecan-1-one Chemical compound CCCCCCCCCCCC(=O)N1CCCCCC1 MXDYUONTWJFUOK-UHFFFAOYSA-N 0.000 description 1
- VNEWJRXBYULGIA-UHFFFAOYSA-N 1-(azepan-1-yl)ethanone Chemical compound CC(=O)N1CCCCCC1 VNEWJRXBYULGIA-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- HDCUSMZVZWLDRZ-UHFFFAOYSA-N 1-benzyl-2-methylhydrazine Chemical compound CNNCC1=CC=CC=C1 HDCUSMZVZWLDRZ-UHFFFAOYSA-N 0.000 description 1
- FPHSHEGTNPFMRN-UHFFFAOYSA-N 1-chloro-2-ethylhydrazine Chemical compound CCNNCl FPHSHEGTNPFMRN-UHFFFAOYSA-N 0.000 description 1
- BHDDSIBLLZQKRF-UHFFFAOYSA-N 1-dodecylpiperidine Chemical compound CCCCCCCCCCCCN1CCCCC1 BHDDSIBLLZQKRF-UHFFFAOYSA-N 0.000 description 1
- FFYRIXSGFSWFAQ-UHFFFAOYSA-N 1-dodecylpyridin-1-ium Chemical compound CCCCCCCCCCCC[N+]1=CC=CC=C1 FFYRIXSGFSWFAQ-UHFFFAOYSA-N 0.000 description 1
- ILAAKLLNCXMODT-UHFFFAOYSA-N 1-hexyl-2-methylhydrazine Chemical compound CCCCCCNNC ILAAKLLNCXMODT-UHFFFAOYSA-N 0.000 description 1
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical class ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- ZAZBXUDPQJLMIK-UHFFFAOYSA-N 3-methylbutan-1-ol;pentan-1-ol Chemical compound CCCCCO.CC(C)CCO ZAZBXUDPQJLMIK-UHFFFAOYSA-N 0.000 description 1
- GSMSOLOCRKCJMR-UHFFFAOYSA-N 4-octadecylmorpholine Chemical compound CCCCCCCCCCCCCCCCCCN1CCOCC1 GSMSOLOCRKCJMR-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- HSEMFIZWXHQJAE-UHFFFAOYSA-N Amide-Hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- KTGBNRUVXPZFLF-UHFFFAOYSA-N C1C(NNCC)C1 Chemical compound C1C(NNCC)C1 KTGBNRUVXPZFLF-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PDQAZBWRQCGBEV-UHFFFAOYSA-N Ethylenethiourea Chemical compound S=C1NCCN1 PDQAZBWRQCGBEV-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- RGMZNZABJYWAEC-UHFFFAOYSA-N Methyltris(trimethylsiloxy)silane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C RGMZNZABJYWAEC-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- XKLVLDXNZDIDKQ-UHFFFAOYSA-N butylhydrazine Chemical compound CCCCNN XKLVLDXNZDIDKQ-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- LHQRDAIAWDPZGH-UHFFFAOYSA-N cyclohexylhydrazine Chemical compound NNC1CCCCC1 LHQRDAIAWDPZGH-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GPSINNCBFURFNQ-UHFFFAOYSA-N cyclopropylhydrazine Chemical compound NNC1CC1 GPSINNCBFURFNQ-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- VKYBUEJAQKBUFU-UHFFFAOYSA-N hexylhydrazine Chemical compound CCCCCCNN VKYBUEJAQKBUFU-UHFFFAOYSA-N 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 238000007733 ion plating Methods 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 108010059345 keratinase Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229940073663 methyl trimethicone Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- SWYVHBPXKKDGLL-UHFFFAOYSA-N n,n,3-trimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C)=C1 SWYVHBPXKKDGLL-UHFFFAOYSA-N 0.000 description 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- KJAQRHMKLVGSCG-UHFFFAOYSA-N propan-2-ylhydrazine Chemical compound CC(C)NN KJAQRHMKLVGSCG-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical composition for improving drug permeation for treating keratoconjunctive fungal infections, a method for preparing the same, and a method for administering the composition. Specifically, the present invention provides a pharmaceutical composition comprising: a) at least one antifungal active substance; b) an alkalizing agent which can be adjusted to pH 7 to pH 13; And c) an organic solvent containing an antifungal active ingredient dissolving or promoting absorption to increase absorption of keratin tissue to prevent and treat fungal infectious diseases.
Description
The present invention relates to a pharmaceutical composition for treating fungal infections capable of improving drug permeation into keratin tissues.
Keratin is a protein that forms the basis of the epithelial structure. It is made up of various amino acids such as glutamic acid and arginine. The content of cysteine is high, and typical tissues include hair, claws, and skin.
Trichophtosis is caused by infection of hair, hands and toenails by dermatophyte. Dermatophyte has keratinase which can dissolve keratin. Therefore, it is important that keratinous tissue It can easily invade, live the horny nutrients, and cause various lesions. These dermatophytes are known to be various species, but Trichophyton rubrum and Trichophyton mentagrophytes are representative.
Onychomycosis, a kind of ringworm, is a common disease that affects about 20% of the whole population, especially on the thumb nail and thumb nail, and mainly occurs on the nail bed of the dermatophagus. And penetrate through the nail. The occurrence of nail fungus in smokers, peripheral vascular disease patients and diabetic patients is well developed, especially in the elderly. Patients with nail fungus feel a sense of cosmetic discomfort such as thickening of the hands and nails and becoming opaque, and functional disorders such as breakage of hands and toenails and breakage occur. Treatment may also be necessary due to possible contact with other parts of the body or other persons through contact.
There are five clinically significant types of nail fungus. The lesions were divided into two groups: distal nail parotypes (DSO), white superficial nail fungus (WSO), proximal nail paraplegia (PSO), nail paraplegia (EO) Distal nail-to-shoulder fungus (DSO) is a case in which the foot and tines are transferred to the nail. The dermatophytes infiltrate the inside of the nail plate through the stratum corneum of the distal nail and the nail of the nail, It is the most common form of toenail fungus that progresses to the proximal part in the opposite direction. The superficial nail fungus (WSO) is a case of the causative bacteria invading the surface of the nail plate, which is called white superficial nail fungus with small white spots with clear boundaries on the nail plate. Proximal nail paraplegia (PSO) is transmitted through the lower stratum corneum of the proximal paraplegia of the nail. Because the fungi are present in the lower part of the nail plate, the inflammation reaction is less and the surface of the nail plate looks normal but the nail palate is accompanied by the fact that it does not invade the nail plate. This is because most of the causative bacteria of the nail fungus are not only distributed in the nail plate but also penetrate into the lower nail of the nail plate, so that the core of the nail fungus treatment must eradicate the causative bacteria .
The treatment of nail fungus is most commonly used as first-line treatment of terbinafine, which has good antibacterial activity against dermatophytes and fungi, and daily 250 mg of terbinafine hydrochloride is taken daily for 12 weeks. Complete cure, in which both mycological cure and clinical cure occurs, is reported to be approximately 38%. Oral administration of azole-based antifungal agents such as itraconazole and fluconazole, which have a lower clinical cure rate than terbinafine, is often used. However, the above-mentioned oral antifungal agents have side effects such as gastrointestinal diseases, headache, and rash, and occasionally, fatal side effects such as hepatotoxicity may occur. Therefore, monitoring of liver function such as blood test is necessary. There are restrictions.
The other methods for treating nail fungus include the administration of a local solvent such as cyclopirox, amoropine and thioconazole directly to the hands and toenails, thereby minimizing side effects and inconveniences of such oral solutions. However, the hands and toenails are about 100 times thicker than the stratum corneum of the skin, and the tissues forming the hand and toenails are tightly bound through the sulfide linkage with a protein called α-keratin, making it difficult to penetrate the drug. Therefore, topical medicines administered directly on the hands and toenails, such as cyclopirox (Penrox, ropurox and sanofi-aventis), show a low complete cure rate of only 5.5 to 8.5% at 12 months cure.
Therefore, it is a big task in the art to remove the side effects such as hepatotoxicity by topical administration and to develop a therapeutic agent for the nail fungus which is more effective than the conventional commercialized therapeutic agent. For this purpose, it is essential to improve the permeability of the drug through the hand and toenails which are difficult to penetrate the drug, and various attempts have been made heretofore.
Korean Patent Laid-Open Publication No. 2012-38444, Korean Patent Laid-Open Publication No. 2014-25341, and Korean Laid-Open Patent Publication No. 2012-15319 disclose an antifungal active substance, a solvent at least capable of dissolving an antifungal agent, and an organic acid as a permeation enhancer Compositions are disclosed.
International Patent Publication No. WO 2010-010470 and U.S. Patent No. 7,740,875 disclose a composition having a pH of 7.0 or less which enhances the hand, claw or skin permeability of an active substance by using a phospholipid and a surfactant in the active substance.
European Patent Publication No. 0777457 and U.S. Patent No. 5,346,692 are readily applicable on the nails and form a film after the volatile solvent is dried to form a hydrophobic film on the antifungal active substance and the volatile solvent so that the antifungal substance can be continuously released A composition comprising the same is disclosed. However, since the water-insoluble film covers the fingernail before the re-administration, the above-described composition has a disadvantage in that it is necessary to remove the film before use in order to prevent the absorption of the re-administered drug.
In order to solve the above inconvenience, a composition for permeating drug penetration of the hand and toenails using a water-soluble polymer is also disclosed. For example, in International Patent Publication No. WO 2002-007683, US Patent No. 8,697,753, British Journal of Dermatology, 2010 162 p311-317, Journal of the European Academy of Dermatology and Venereology 2009 23 p773-781, [Drug Development and Industrial Pharmacy, 31: 11-17, 2005] discloses a composition containing an antifungal agent and using hydroxypropylchitosan and carboxymethylchitosan as water-soluble polymers to increase penetration of the active ingredient. The composition exhibited about twice the improvement in permeability compared to the existing commercial products. However, even after 48 weeks of treatment, the complete cure rate is only 5.7%, which is still very low.
U.S. Patent No. 6,846,837 discloses a composition for treating a lacrimal fungus comprising an antifungal agent and an inorganic alkaline agent such as sodium hydroxide or potassium hydroxide at pH 7.5 to 13.0. However, since the above-mentioned composition, which is simply adjusted to have a pH, is mostly an aqueous solution, it is impossible to dissolve the antifungal agent and penetrate into the fingernail, so that there is a technical limitation that a large amount of the antifungal agent can not penetrate into the fingernail.
As described above, numerous attempts have been made to overcome the disadvantages of oral antifungal agents such as hepatotoxicity in the field of the treatment of the nail fungus and infiltrate the drug into the hands and toenails in order to increase the clinical complete cure rate. However, There is no clinically satisfactory penetration technique for the hands and toenails. Since the age of the palsy is rapidly increasing in the aging society, the age of the palsy is high in the population of the elderly, and it is very inconvenient to taste or function. Therefore, a new excellent treatment method is needed to solve this problem.
While analyzing prior art for studies to improve nasal permeation of antifungal agents, the inventors of the present invention disclosed in Korean Patent Publication No. 2012-38444, Korean Patent Publication No. 2014-25341 and Korean Patent Publication No. 2012-15319 The prior art described in the prior art uses an organic acid such as lactic acid as a permeation enhancer for nasal permeation of the antifungal active substance. The prior art contains an organic acid and the solution becomes acidic, so that the nasal permeation of the antifungal active substance is easy One, however, was found to be less stable in chemical reaction and degradation, and that the solid state was stable.
In addition, the prior art described in U.S. Patent No. 6,846,837 uses an inorganic alkaline agent such as sodium hydroxide and potassium hydroxide dissolved in an aqueous solvent for nasal permeation of an antifungal active substance, and since various antifungal active substances are poorly soluble It was impossible to dissolve in an aqueous solvent and the permeation of drug from the hand and toenails was insufficient.
Surprisingly, the present inventors have found that a composition in which an active ingredient of an antifungal compound is dissolved in an organic solvent and a solution in which the active ingredient of the antifungal compound is dissolved is adjusted to pH 7 to pH 13 is significantly superior in nasal permeability to active ingredient The present inventors have also confirmed that the nasal permeability increases remarkably when the ion introducing apparatus is used in combination with the composition. Based on these results, the present invention has been completed.
It is an object of the present invention to provide a composition capable of significantly increasing the permeation of the antifungal active substance into the nail and thereby increasing the clinical treatment rate or reducing the treatment period.
In order to achieve the above object, the present invention provides a composition capable of maximizing the nasal permeability by locally administering an antifungal active substance.
Hereinafter, the present invention will be described in detail.
The present invention
a) at least one antifungal active substance;
b) an organic solvent capable of enhancing dissolution or permeation of the active ingredient; And
c) an alkalizing agent which can be adjusted to pH 7 to pH 13;
To a pharmaceutical composition for preventing and treating fungal infectious diseases by increasing absorption of keratinous tissue.
The pharmaceutical composition according to the present invention comprises at least one antifungal active substance. In the present invention, the antifungal active substance may be selected from any known antifungal agent of synthetic or natural origin. The following components are examples and may be free acids or bases in their own right, or in the form of their salts.
Examples of the antifungal active substance according to the present invention include 1-hydroxy-2-pyridone compounds and their salts such as cyclopirox, cyclopioxolamine and lilopirox, examples of imidazole derivatives Which is at least one selected from the group consisting of clotrimazole, econazole, isoconazole, ketoconazole, miconazole, thioconazole, butonazole, penticonazole, oxiconazole, butoconazole, seletaconazole, sulconazole, ricinazole, Naphthalene, naphthalene, naphthalene, naphthalene, naphthalene, naphthalene, naphthalene, naphthalene, naphthalene, Salts, such as alvaconazole, epinaconazole, fluconazole, itraconazole, isobuconazole, labuconazole, posaconazole, voriconazole and terconazole, and in addition thereto, Durafunjin, Mika Fenugine, benzoic acid, haloprozin, undecylenic acid, griseofulvin, tonaphthate, and flucytosine, preferably cyclopiox, ketoconazole, amoropine, terbinafine.
The composition of the present invention comprises one or more of the antifungal active substance or substance series, and the contained amount thereof is in a range of the stability and effectiveness of which is known, and ranges from 0.1 to 10 times the concentration of each ingredient in the market desirable.
The present invention is characterized by containing at least one organic solvent. The organic solvent is an organic solvent capable of dissolving the antifungal active substance. The active substance contained in the composition can be present at a certain concentration. When applied to the topical application, the main ingredient is uniformly delivered to the lesion site. Can be increased. It also evaporates quickly after application and minimizes external contamination, making it convenient to use.
Examples of the volatile organic solvent which can be included in the present invention include organic solvents such as alkanes, alcohols, alcohols, esters, ketones, ethers and silicones, , Alcohols such as ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-poroxanol and 1-pentanol 3-methyl-1-butanol; Esters such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, ethyl formate, butyl acetate and the like; Ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone, and methyl isobutyl ketone; Ethers such as ethyl ether, tert-butyl methyl ether, isopropyl ether and petroleum ether; Examples of the organic solvent include heptane, pentane, isooctane, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, methyltetrahydrofuran, anisole, dimethylsulfoxide, isododecane, Organic solvents are preferred. A silicone oil consisting of a siloxane having an organic side chain; Dimethicone, methyltrimethicone, and cyclic acid compounds such as cyclomethicone, dimethicone, hydrogendimethicone, and methicone, and may contain isopropyl alcohol, ethyl acetate, ethanol, acetone, dimethicone Chicone, and cyclomethicone are preferable.
The amount of the organic solvent that can be added to the composition of the present invention is sufficient to dissolve the active substance and facilitate drug delivery to the nares and should be contained in an amount to match the concentration of the appropriate active substance, 5 to 99% by weight, preferably 8 to 98% by weight, more preferably 8 to 90% by weight.
The present invention may contain additional water in addition to the organic solvent as a solvent. At this time, the amount of water that can be contained in the present invention is a sufficient amount to dissolve the antifungal active substance, and may be added at an appropriate concentration to match the effective concentration of the active substance.
The composition of the present invention is also characterized by comprising an alkalizing agent. The alkalizing agent of the present invention may include both an inorganic alkalizing agent and an organic alkalizing agent which increase the pH of the composition according to the present invention. The inorganic alkalizing agent is selected from the group consisting of ammonium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, calcium oxide, sodium acetate, sodium borate, sodium carbonate, sodium hydrogen carbonate, sodium phosphate, potassium carbonate, Potassium, potassium phosphate, ammonium phosphate, etc., and hydrates thereof. Organic alkalizing agents may include primary amines (-NH2), one secondary substituted amine (-NHR), and two substituted tertiary amines (-NRaRb) as amines. Examples of the primary amine include 2-ethanolamine, 2-heptanolamine, 2-amino-2-methyl-1,3-propanediol, 2-amino- , 1,4-butanediamine, n-butylamine, cyclohexylamine, ethylamine, ethylenediamine, methylamine, alpha -methylbenzylamine, phenethylamine, propylamine and trishydroxymethylaminomethane. The secondary amine can be selected from the group consisting of methylaminoamine, ethylaminoamine, isopropylaminoamine, butylaminoamine, cyclopropylaminoamine, cyclohexylaminoamine, n-hexylaminoamine, phenylaminoamine, benzylaminoamine, Hydroxyethylaminoamine, diethanolamine, diethylamine, diisopropylamine, and dimethylamine. The tertiary amine can be selected from the group consisting of dibutylaminoamine, diethylaminoamine, dimethylaminoamine, diisopropylaminoamine, ethylchloroaminoamine, dimethylaminoamine, diisopropylaminoamine, methylchloroethylaminoamine, ethylcyclopropylaminoamine , Methylhexylaminoamine, methylbenzylaminoamine, N, N-diethylaniline, N, N-dimethylglycine, triethanolamine, triethylamine and trimethylamine. Amides have a structural formula of R1- (CO) -NR2-R3- and include, for example, hexamethylene acetamide, hexamethylene octamide, hexamethylene lauramide, hexamethylene palmitamide, N, N, N-dimethylacetamide, N, N-dimethyloctamide, N, N-dimethyldecamide, toluamide, dimethyl-m-toluamide, diethyl- Pyrrolidone, 1-methyl-2-pyrrolidone, 1-methyl-2-pyrrolidone, Dodecyl acacycloheptan-2-one, ethylenethiourea, hydantoin, hydroxyurea, imidanilylurea, N-octadecylmorpholine, dodecylpyridinium, N-dodecylpyrrolidide , N-dodecylpiperidine, and N-dodecylhoffepiperidine. Other basic amino acids such as lysine, arginine, meglumine and the like may be included.
The alkalizing agent according to the present invention may be varied depending on the solubility and stability of the antifungal active substance and may be an alkalizing agent capable of adjusting the pH to 7 to 13 when the composition itself or the composition is diluted with water, desirable. The amount of the alkalizing agent according to the present invention may vary depending on the strength of the base, the molecular weight, the number of the hydroxyl (OH-) ions which can be dissociated, and the kind of acid contained in the preparation. The pH is preferably 6 to 14, more preferably 7 to 13.
The present invention may further comprise a film former. In this case, when the composition of the present invention is applied to a lesion site, a film-forming agent can form a film at a lesion site so that it can be uniformly applied to a certain thickness, and an organic solvent can prevent crystallization of a viral article even after volatilization, To maintain sustained delivery of the drug to the nail. The film-forming materials that may be further included in the present invention include chitosan, chitosan derivatives or salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, carbomer, PVP / MA, HP Acrylate copolymer, an ethyl acrylate / methacrylate copolymer, an aminoalkyl methacrylate copolymer, an ammonium methacrylate copolymer, a PVP / VA copolymer, a PVA , PVA / MA butyl ester copolymers, shellac, and alkyl acrylate copolymers, hydroxypropylcellulose phthalate, hydroxypropylcellulose acetate succinate, acrylate / dimethicone copolymers, and trimethylsiloxysilicate. The amount of the film-forming agent which may be contained in the present invention is 0.1 to 20% by weight, preferably 0.2 to 15% by weight.
The composition of the present invention is an excipient that is convenient to administer, improves feeling, enhances formulation stability, and increases penetration of drugs into the nail. In addition to the above essential components, the composition of the present invention includes plasticizers, thickeners, surfactants , An auxiliary dissolving agent, a preservative, a flavoring agent and the like, examples of which are well illustrated in Handbook of Pharmaceutical Excipients 7th edition (Raymond C. Rowe).
In addition, the present invention can be formulated in units of one or more formulations. The composition of the present invention can be administered in a single dosage unit, but it is also possible to use a first agent containing an alkalizing agent and a second agent in the form of a second agent form containing the drug and the organic solvent or a combination of an alkalizing agent 1, A solvent, and a solvent.
In addition, the composition of the present invention can be applied with iontophoresis, which increases the absorption of drugs by giving a potential difference to the skin or nails during administration. Ion implantation may include any method of maintaining a constant voltage or maintaining a constant current to provide a potential difference. The composition of the present invention shows a remarkable increase in permeability by itself, but shows a remarkable increase in permeability when the ion plating method is applied together.
The present invention allows high-concentration penetration of an excellent antifungal active substance into keratin tissues and enables treatment of intractable white pneumonia in the tissues. Increase the rate of complete cure, or shorten the minimum administration period for complete treatment. In addition, the drug can be infiltrated at a high concentration by a single administration, and the concentration can be maintained at an effective concentration for a long time in the tissue, thereby increasing the administration interval and reducing the number of administrations.
Fig. 1 is a graph showing the results of a comparison between the results of Examples 1, 5, 8, 9, 10, 11, and 21 evaluated using a cow foot slice and Comparative Example 1 as a comparative example, Which represents the cumulative amount of permeation over time.
FIG. 2 is a graph showing the cumulative permeation amounts of antibacterial active materials contained in Examples 12 to 17 evaluated using cow foot slices, Comparative Example 1 as a comparative example, and Lofu Rox, a full-scale commercial product, for 48 hours.
FIG. 3 is a graph showing the cumulative permeation amounts of the antibacterial active materials in Examples 29 to 34 evaluated using the bovine cut pieces and Comparative Example 1 and Comparative Example 1 for 4 hours. 3 is an enlarged view of Example 29 and Comparative Example 1. FIG.
Hereinafter, the present invention will be described in detail with reference to examples.
However, the following examples are illustrative of the present invention, and the contents of the present invention are not limited by the following examples.
≪ Examples 1 to 4 > Preparation of a composition containing an antifungal active substance according to the present invention
A part of (about 50% equivalent) organic solvent was added to the antifungal active substance, the alkalizing agent and other substances in the composition shown in Table 1 below, and the solution was completely dissolved by using an overhead mixer. Separately, the remaining organic solvent is placed in a Homo-Agi Mixer, and then a film-forming material (polymer such as hydroxypropylcellulose) is added to dissolve or disperse the solution. Then, a solution containing the active material is added thereto and mixed thoroughly. The compositions were prepared and described in Examples 1 to 4, respectively. In order to confirm the pH of Examples 1 to 4, purified water was diluted with an amount of 10 times the total amount, and pH was measured. The results are shown in Table 1.
≪ Examples 5 to 11 > Preparation of compositions containing antifungal active substances, including various alkalizing agents
A pharmaceutical composition for the treatment of fungal infectious diseases comprising various alkalizing agents according to the present invention was prepared with the composition shown in Table 2 below. An antifungal active substance, an alkalizing agent and an acrylate / ammonium methacrylate copolymer were put into an organic solvent or an organic solvent and a purified water mixed solvent and completely dissolved by using an overhead mixer to prepare a solution. In order to confirm the pH, purified water was diluted to 10 times the total amount, and the pH was measured. The results are shown in Table 2.
≪ Examples 12 to 17 > Preparation of compositions containing antifungal active substances, including various organic solvents
In the same manner as in Examples 5 to 11, compositions for treating fungal infection were prepared using various organic solvents as shown in Table 3 below.
< Example 18 to 22> variety Organic solvent Preparation of a composition containing an antifungal active substance containing
In the same manner as in Examples 1 to 4, a composition for treating fungal infection was prepared using an organic solvent and purified water as shown in Table 4 below.
≪ Examples 23 and 24 > Preparation of composition for divided administration
As shown in Table 5, monoethanolamine was added to purified water, an ethanol mixed solvent or ethanol, and the mixture was dissolved in an overhead mixer and dissolved in 1 part. Then, cyclopropyl or amorphous hydrochloride was added to isopropyl alcohol, purified water or ethylacetate and mixed with an overhead mixer To prepare a second agent.
≪ Examples 25 to 27 > Preparation of a composition containing at least one antifungal active substance
In the same manner as in Examples 1 to 4, a composition for treating fungal infection was prepared in the same manner as the amount shown in Table 6 below. To confirm the pH, purified water was diluted to 10 times the total amount, and the pH was measured. The results are shown in Table 6.
≪ Examples 29 to 34 > Composition containing an antifungal active substance and an alkalizing agent and ion-applying method
As shown in Table 7 below, the active substance (cyclopirox) and the film-forming substance (hydroxypropylcellulose) were completely dissolved in an organic solvent in the same manner as in Example 1-4 using an overhead mixer (Example 29 ~ 34). The bovine hoof was cut to a certain thickness and maintained at a constant voltage of 9 V or a constant current of 0.05, 0.1, 1, or 10 mA using a Franz diffusion cell and a DC power supply as a power supply device 30-34). In order to allow the current to flow, a negative electrode is applied to the donor phase and a positive electrode is applied to the receptor phase.
≪ Comparative Example 1 & The preparation of the preparation described in Example 1
As shown in the following Table 8, the composition of Example 1 of U.S. Patent No. 6,846,837 was prepared so that 8% of cyclophirox was added.
<Experimental Example 1> Evaluation of keratinous tissue permeability by pH
The bovine hoof was cut to a certain thickness and the permeability of the antifungal active substance was evaluated by using Franz diffusion cell.
Examples 1, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 21 and Comparative Example 1 (Example 1 of U.S. Patent No. 6,846,837, a commercially available product pool Care ® (Korea menari you), ropu Rocks ® (Sanofi-German &) were used as controls. Cumulative noodle permeability at 48 hours from the start of the test is shown in Figs.
As can be seen in Figures 1 and 2, the permeability of the active material was significantly increased in the composition of the present invention compared to the comparative example.
<Experimental Example 2> Evaluation of keratinous tissue permeability upon application of the compositions and iontophoresis devices of Examples 29 to 34 according to the present invention
The keratinous tissue permeability of Comparative Example 1 and Examples 29 to 34 was evaluated. The cumulative noodle permeability at 4 hours from the start of the test is shown in Fig. As can be seen from FIG. 3, the composition of the present invention showed significantly increased transmittance compared to comparative examples and commercially available products. Surprisingly, the iontophoresis significantly increased the permeability of the active material compared to when the iontophoresis was not applied.
Claims (16)
b) 80 to 89.5% by weight of an organic solvent selected from ethanol, isopropyl alcohol, acetone, ethyl acetate, dimethicone or cyclomethicone;
c) from 0.5 to 5% by weight of one or two alkalizing agents selected from 2-amino-2-methyl-1-propanol, monoethanolamine, diethanolamine or triethanolamine; And
d) a film forming agent selected from hydroxypropylcellulose, acrylate / ammonium methacrylate copolymer, hydroxypropylmethylcellulose phthalate, 2 wt%
And increasing absorption in a keratinous tissue having a pH ranging from 8 to 13 to prevent and treat fungal infectious diseases.
b) 56% by weight isopropyl alcohol;
c) from 1.5 to 4% by weight of sodium hydroxide or monoethanolamine;
d) 2% by weight of hydroxypropylcellulose or acrylate / ammonium methacrylate copolymer and
e) purified water 25 to 32.5 wt%
And increasing absorption in a keratinous tissue having a pH ranging from 8 to 13, thereby preventing and treating fungal infectious diseases.
b) 61.7% by weight of isopropyl alcohol;
c) 2.6% by weight of potassium hydroxide;
d) 0.5% by weight of hydroxypropylcellulose; And
e) Purified water 27.2 wt%
To increase the absorption in the keratin tissue by increasing the permeation of cyclophilus to flow through a current of 0.05 to 10 mA into the pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2016/002415 WO2016144121A2 (en) | 2015-03-12 | 2016-03-10 | Pharmaceutical composition for treating fungal infectious diseases of ketratin tissue |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150034395 | 2015-03-12 | ||
| KR1020150034395 | 2015-03-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160110209A KR20160110209A (en) | 2016-09-21 |
| KR101799008B1 true KR101799008B1 (en) | 2017-11-17 |
Family
ID=57080085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160028730A KR101799008B1 (en) | 2015-03-12 | 2016-03-10 | Pharmaceutical composition for treating fungal infections of keratinous tissue |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101799008B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020204279A1 (en) | 2019-04-01 | 2020-10-08 | 전남대학교 산학협력단 | Composition for diagnosis of fungal infection |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102072946B1 (en) | 2019-08-06 | 2020-02-03 | 주식회사 씨엔엘바이오텍 | Composition for prevention or treatment of nail fungus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001523273A (en) | 1998-02-09 | 2001-11-20 | マクロケム・コーポレーシヨン | Antifungal nail lacquer and method of using same |
| US6846837B2 (en) | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
-
2016
- 2016-03-10 KR KR1020160028730A patent/KR101799008B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001523273A (en) | 1998-02-09 | 2001-11-20 | マクロケム・コーポレーシヨン | Antifungal nail lacquer and method of using same |
| US6846837B2 (en) | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020204279A1 (en) | 2019-04-01 | 2020-10-08 | 전남대학교 산학협력단 | Composition for diagnosis of fungal infection |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160110209A (en) | 2016-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI78235B (en) | REFERENCE TO A FRAME EXISTING ANTI-INFLAMMATOR COMPOSITION IN GELSALVAFORM. | |
| US20110020474A1 (en) | Methods of Treating Infections of the Nail or Skin Using Hypohalite | |
| JP2005503318A (en) | Pharmaceutical composition | |
| JP6503303B2 (en) | Pharmaceutical composition for the treatment of fungal infections | |
| KR101333892B1 (en) | Antifungal composition | |
| JP2012526727A (en) | Composition suitable for topical treatment of fungal infections of the skin and nails | |
| KR101799008B1 (en) | Pharmaceutical composition for treating fungal infections of keratinous tissue | |
| EP3236938B1 (en) | Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol | |
| EP2692332B1 (en) | Composition for the treatment of callus, corns and psoriasis | |
| US8236814B2 (en) | Composition and method for treatment of warts | |
| KR101690765B1 (en) | Transdermal formulation comprising antifungal agent | |
| US20170258746A1 (en) | Acetic acid/thymol compositions and their use in the treatment of onychomycosis | |
| US20140079804A1 (en) | Compositions and methods for treatment of infections | |
| JPH02193932A (en) | Percutaneous and transmucosal absorbefacient and percutaneous and transmucosal pharmaceutical | |
| JP2006501223A (en) | How to treat a fungal infection | |
| US11154542B2 (en) | Nail lacquer composition containing ciclopirox | |
| JPH111433A (en) | Tolnaftate-containing liquid agent | |
| WO2016144121A2 (en) | Pharmaceutical composition for treating fungal infectious diseases of ketratin tissue | |
| RU2238092C2 (en) | Aqueous medicinal composition for treatment of skin disease | |
| CA2830406C (en) | Compositions and methods for treatment of infections | |
| JP6016085B2 (en) | Antifungal composition for external use and method for applying antifungal composition for external use | |
| JP2021525808A (en) | Hypoallergenic composition for topical treatment of skin and nail disorders caused by viruses and fungi | |
| AU2015213427A1 (en) | Compositions and methods for treatment of infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20191127 Year of fee payment: 4 |